Bitesize briefing – clinical trials, outcomes and endpoints

Published on 17 April 2019
 

In this briefing Sabah Meddings of the Sunday Times and healthcare analyst Andy Smith discuss his recent note, Trial outcomes and value – explaining contemporary clinical trial issues. They discuss how the detail of pharmaceutical and biotechnology company clinical trials is relevant to investors. They also touch on the debate surrounding the confidentiality of interactions between drug sponsors and regulators and whether this is material to investors.

Share this with friends and colleagues